CD19 and Miyoshi myopathy: At the 2020 ASH annual meeting, investigators reported early results from the first-in-human multicenter clinical study (NCT04236011; NCT04182581) BCMA-CD19-directed FasTCAR T (GC012F) in 16 patients with R/R MM.